Novo Nordisk and China Resources Pharmaceuticals work together to lay out the growth and development fields.

On July 15, Novo Nordisk (China) Pharmaceutical Co., Ltd. (hereinafter: Novo Nordisk) and China Resources Pharmaceutical Group Co., Ltd. (hereinafter: China Resources Pharmaceuticals) announced that, based on the earlier letter of intent signed by the two sides, Novo Nordisk and China Resources Pharmaceutical Co., Ltd. (China Resources 39) will jointly promote the recombinant human growth hormone injection ® in Chinese mainland through a contract sales model.
the partnership, which will take effect on August 1, 2020, aims to further enhance the accessibility of Nozer ® in China and benefit more Chinese patients.
this cooperation, China Resources 39 will be responsible for the academic promotion of Nozer ® in the country, its wholly-owned subsidiary China Resources North Trade Pharmaceutical Management Co., Ltd. will be responsible for the specific implementation.
Novo Nordisk headquarters remains the owner of Nozer ®, and the Listing LicenseE (MAH) will continue to be responsible for the production of Norze's ® products, leading medical strategy and medical interaction, and providing full support to patients through a patient hotline.
relying on Novo Nordisk's decades of innovation and experience in the field of recombinant human growth hormone, as well as China Resources' high-quality academic promotion capabilities and extensive business network in the field of pediatrics, the two sides will consolidate and expand Norze ®'s academic outreach network, further expand its accessibility, provide medical professionals with quality treatment options, and make it easier for patients to access Nordisk's research and development and production of high-quality products.
in response to the unmet needs of china's dwarfism, Novo Nordisk continues to introduce better and better drugs and injection devices to improve compliance and treatment outcomes by improving patient systocrancy experience.
the two sides will take this cooperation as an opportunity to continue to lay out the field of growth and development.
as Novo Nordisk's second largest market in the world, Greater China is in an important strategic position in the company's global footprint.
Novo Nordisk will continue to invest in the Chinese market and better serve Chinese patients. "Innovation and collaboration are the cornerstones of our efforts to transform diabetes and other serious chronic diseases in China," said Ms. Zhou Xiaping, Senior Vice President and President of Greater China,
Novo Nordisk.
as a 'patient-centric' company that focuses on the needs of unmet patients and is committed to exploring more effective collaborative models that deliver high-quality innovative treatment sourcing options for doctors and patients.
is pleased to work with China Resources 39, a subsidiary of China Resources Pharmaceuticals, to jointly improve the availability of high-quality and innovative drugs, benefit more children with dwarf diseases in China, and help them improve their quality of life. "Nozer ® is a global leading brand of growth hormone, and the efficacy and safety of the treatment and safety are widely recognized by doctors and patients," said Mr. Qiu Huawei, President of China Resources 39,
.
relying on Novo Nordisk's deep accumulation in the field of growth hormone, as well as our extensive network of channels, we will achieve long-term business win-win through innovative models, this has benefited many patients around the world of imported primary research drugs, to bring more needy Chinese patients.
" as the world's leading biopharmaceutical company and the leading domestic pharmaceutical and health industry listed companies, Novo Nordisk and China Resources Pharmaceuticals through this cooperation will give full play to the advantages of both sides, practice the "patient-centered" commitment, for Chinese patients to bring more high-quality innovative drugs, improve access to drugs, and jointly help "Healthy China 2030" planning objectives.
on Nozer ® Nozer ® is Noord's research and development and production of recombinant human growth hormone products, produced in Denmark, has been listed in more than 100 countries and regions, accumulated more than 30 years of global clinical experience and safety data, is the first use can be saved at 25 oC below 21 days of pre-filled water-filled growth hormone growth hormone.
2018, Nozer ® was approved for listing in China.
As of July 2020, Nozer ® is the only imported water-based growth hormone listed in China and is approved for growth disorders caused by inadequate production of growth hormone in children, growth disorders in girls due to stunting of the adenofle (Turner syndrome), pre-adolescent childhood growth retardation due to chronic kidney disease, small size in children due to Noonan syndrome, and adult growth hormone deficiency.
Nozer ® NordiFlex ® is a growth hormone pre-filled injection pen, available in three different sizes: 5mg, 10mg and 15mg, withno mixing and loading, easy to use and self-injection in just three steps.
Novo Nordisk, founded in 1923, is a leading global biopharmaceutical company headquartered in Denmark.
our goal is to drive change to combat diabetes, and other serious chronic diseases such as obesity, rare blood diseases, endocrine disorders, and so on.
to achieve this goal, we lead scientific breakthroughs, expand the company's drug accessibility, and work to prevent and ultimately cure diseases.
Novo Nordisk employs approximately 431,000 people in 80 countries and territories, providing products and services to more than 170 countries and territories worldwide.
about China Resources Pharmaceutical Group Co., Ltd. China Resources Pharmaceutical Group Co., Ltd. (Stock Exchange of Hong Kong: 3320. HK) is a leading integrated pharmaceutical company in China, covering the production, distribution and retailing of pharmaceutical and healthcare products.
Companies include China Resources 39 Pharmaceutical Co., Ltd., China Resources Pharmaceutical Shuanghe Pharmaceutical Co., Ltd., China Resources Shuanghe Pharmaceutical Co., Ltd., China Resources Jiangzhong Pharmaceutical Group Co., Ltd., DongA Gum Co., Ltd., China Resources Zizhu Pharmaceutical Co., Ltd., China Resources Biopharmaceutical (Shenzhen) Co., Ltd., China Pharmaceutical Research and Development Center Co., Ltd. and other enterprises.
2019, China Resources Pharmaceutical Group achieved operating income of HK$204.454 billion.
about China Resources 39 Pharmaceutical Co., Ltd. China Resources 39 is a large state-controlled pharmaceutical listed company under China Resources Pharmaceuticals, mainly engaged in the research and development of pharmaceutical products, production, sales and related health services.
listed on the Shenzhen Stock Exchange on March 9, 2000 (stock code 000999), officially entered China Resources Pharmaceutical Group in 2008.
company's product coverage of a wide range of products, product lines rich.
self-diagnosis and treatment business covers pediatrics, colds, skin, gastrointestinal, cough, orthopaedics and other nearly 10 categories, prescription drug business varieties covering pediatrics, tumors, cardiovascular, digestive system, orthopaedics and other therapeutic areas.
China Resources North Trade Pharmaceutical Management Co., Ltd. is a wholly owned subsidiary of China Resources 39, mainly responsible for the promotion and sales of prescription drugs business.
.